



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

September 28, 2018

Isa Odidi, Ph.D., MBA  
Chief Executive Officer  
Intellipharmaceutics International Inc.  
30 Worcester Road  
Toronto, Ontario  
Canada, M9W 5X2

**Re: Intellipharmaceutics International Inc.**  
**Registration Statement on Form F-1**  
**Filed September 20, 2018**  
**File No. 333-227448**

Dear Dr. Odidi:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Ada D. Sarmento at 202-551-3798 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Healthcare & Insurance

cc: Richard DiStefano, Esq.